Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)

 

Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)

Contact Information: Anthony Marciano SHARE THIS POST Apricus Biosciences NewsMORE your MARKET VIEW Related Stocks Find News …

More Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002) Videos

Leave a Reply